Mercks-Pembrolizumab-Immunotherapy-Drug-for-Skin-and-Lung-Cancer-640x360

News Flash: Merck confirm anti-PD-1 melanoma phase II drug trial

Anti-PD-1 Melanoma Phase II Drug Trial

Report from Chicago today.  The drug company Merck, confirm that the anti-PD-1 melanoma phase II drug trial is complete and the data are very impressive.  Monotherapy with the drug has shown a major survival benefit in advanced melanoma.

The drug, previously discussed in this blog, is essentially a booster to the patients own immune system which prevents the melanoma cells from avoiding detection by immune cells

Phase III clinical trials will be commenced later this year.  If you or someone you know, suffers from advanced melanoma, contact your dermatologist or oncologist for further information.